141 related articles for article (PubMed ID: 6222845)
1. Clinical pharmacology of the anticancer polypeptide neocarzinostatin.
Hall SW; Knight J; Broughton A; Benjamin RS; McKelvey E
Cancer Chemother Pharmacol; 1983; 10(3):200-4. PubMed ID: 6222845
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial and clinical pharmacology of elsamitrucin.
Raber MN; Newman RA; Newman BM; Gaver RC; Schacter LP
Cancer Res; 1992 Mar; 52(6):1406-10. PubMed ID: 1540949
[TBL] [Abstract][Full Text] [Related]
3. Human pharmacokinetics of a new acridine derivative, 4'-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992).
Hall SW; Friedman J; Legha SS; Benjamin RS; Gutterman JU; Loo TL
Cancer Res; 1983 Jul; 43(7):3422-6. PubMed ID: 6687834
[TBL] [Abstract][Full Text] [Related]
4. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
5. Prophylactic effects of perioperatively administered neocarzinostatin in renal cell carcinoma.
Satake I; Tari K; Ohwada F; Saitoh T; Negishi T
Nihon Gan Chiryo Gakkai Shi; 1989 Apr; 24(4):809-16. PubMed ID: 2528598
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of accumulation of the antitumor protein antibiotic neocarzinostatin in bladder tissue: intravenous administration, urinary excretion, and absorption into bladder tissue.
Maeda H; Sakamoto S; Ogata J
Antimicrob Agents Chemother; 1977 Jun; 11(6):941-5. PubMed ID: 141906
[TBL] [Abstract][Full Text] [Related]
7. Bleomycin clinical pharmacology by radioimmunoassay.
Hall SW; Strong JE; Broughton A; Frazier ML; Benjamin RS
Cancer Chemother Pharmacol; 1982; 9(1):22-5. PubMed ID: 6183016
[TBL] [Abstract][Full Text] [Related]
8. Neocarzinostatin in cancer chemotherapy (review).
Maeda H
Anticancer Res; 1981; 1(3):175-86. PubMed ID: 6211130
[TBL] [Abstract][Full Text] [Related]
9. Neocarzinostatin: a phase I clinical trial with five-day intermittent and continuous infusions.
McKelvey EM; Burgess MA; McCredie KB; Murphy WK; Bodey GP
Cancer; 1979 Oct; 44(4):1182-8. PubMed ID: 159119
[TBL] [Abstract][Full Text] [Related]
10. Phase I study with neocarzinostatin: tolerance to two hour infusion and continuous infusion.
Ohnuma T; Nogeire C; Cuttner J; Holland JF
Cancer; 1978 Oct; 42(4):1670-9. PubMed ID: 152143
[TBL] [Abstract][Full Text] [Related]
11. Neocarzinostatin: report of a phase II clinical trial.
McKelvey EM; Murphy W; Zander A; Bodey GP
Cancer Treat Rep; 1981; 65(7-8):699-701. PubMed ID: 6454486
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic analysis of neocarzinostatin in normal and tumor-bearing rodents.
Lowenthal IS; Parker LM; Greenblatt DJ; Brown BL; Samy TS
Cancer Res; 1979 May; 39(5):1547-51. PubMed ID: 154972
[No Abstract] [Full Text] [Related]
13. Zinostatin (neocarzinostatin).
Issell BF; Prestayko AW; Comis RL; Crooke ST
Cancer Treat Rev; 1979 Dec; 6(4):239-49. PubMed ID: 161199
[No Abstract] [Full Text] [Related]
14. A pharmacokinetic simulation model for chemotherapy of brain tumor with an antitumor protein antibiotic, neocarzinostatin. Theoretical considerations behind a two-compartment model for continuous infusion via an internal carotid artery.
Maeda H; Sano Y; Takeshita J; Iwai Z; Kosaka H; Marubayashi T; Matsukado Y
Cancer Chemother Pharmacol; 1981; 5(4):243-9. PubMed ID: 6455212
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacology of bruceantin by radioimmunoassay.
Fong KL; Ho DH; Benjamin RS; Brown NS; Bedikian A; Yap BS; Wiseman CL; Kramer W; Bodey GP
Cancer Chemother Pharmacol; 1982; 9(3):169-72. PubMed ID: 7160053
[TBL] [Abstract][Full Text] [Related]
16. [Part I. Theory and computer simulation for cerebrospinal infusion].
Maeda H; Matsukado Y; Iwai Z; Uemura S; Kuratsu J; Takeshita J; Sano Y
Gan To Kagaku Ryoho; 1982 Jul; 9(6):1040-5. PubMed ID: 6223592
[TBL] [Abstract][Full Text] [Related]
17. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
Abigerges D; Chabot GG; Armand JP; Hérait P; Gouyette A; Gandia D
J Clin Oncol; 1995 Jan; 13(1):210-21. PubMed ID: 7799022
[TBL] [Abstract][Full Text] [Related]
18. Phase I and pharmacologic studies of topotecan in patients with impaired hepatic function.
O'Reilly S; Rowinsky E; Slichenmyer W; Donehower RC; Forastiere A; Ettinger D; Chen TL; Sartorius S; Bowling K; Smith J; Brubaker A; Lubejko B; Ignacio V; Grochow LB
J Natl Cancer Inst; 1996 Jun; 88(12):817-24. PubMed ID: 8637048
[TBL] [Abstract][Full Text] [Related]
19. [Neocarzinostatin: molecular mechanism of action and prospects for clinical use].
Köhnlein W; Jung G
Arzneimittelforschung; 1982; 32(11):1474-9. PubMed ID: 6217819
[TBL] [Abstract][Full Text] [Related]
20. Phase I clinical and pharmacological study of merbarone.
Dimaggio JJ; Warrell RP; Muindi J; Stevens YW; Lee SJ; Lowenthal DA; Haines I; Walsh TD; Baltzer L; Yaldaei S
Cancer Res; 1990 Feb; 50(4):1151-5. PubMed ID: 2297763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
